Selected article for: "effector cell and target cell"
Title: Development of graft-vs.-host disease-like syndrome in cyclosporine- treated rats after syngeneic bone marrow transplantation. I. Development of cytotoxic T lymphocytes with apparent polyclonal anti-Ia specificity, including autoreactivity
  • Document date: 1985_4_1
    • ID: rqggh4y2_34
    Snippet: Lethally irradiated rats reconstituted with syngeneic bone marrow and treated with cyclosporine (CsA) for 40 d develop a graft-vs.-host disease-like syndrome (GVHD) after CsA therapy. We attempted to assess the development of autoreactivity in these animals. Results revealed that a majority of the animals with syngeneic GVHD develop autocytotoxic T lymphocytes of the OX8 phenotype. In addition to reactivity with self, these cells were capable of .....
    Document: Lethally irradiated rats reconstituted with syngeneic bone marrow and treated with cyclosporine (CsA) for 40 d develop a graft-vs.-host disease-like syndrome (GVHD) after CsA therapy. We attempted to assess the development of autoreactivity in these animals. Results revealed that a majority of the animals with syngeneic GVHD develop autocytotoxic T lymphocytes of the OX8 phenotype. In addition to reactivity with self, these cells were capable of lysing appropriate target cells from a variety of different rat strains. The target antigens appeared to be class II major histocompatibility antigens, because lysis could be effectively blocked by an anti-Ia monoclonal antibody. Cold target inhibition studies indicated that one effector cell was capable of lysing various target cells, and provided evidence against a polyclonal activation of multiple anti-Ia-reactive cells. These results suggested that the anti-class II autoreactive cell associated with syngeneic GVHD either recognizes a common class II determinant ("public" epitope) shared by multiple strains of rats, or was polyspecific with respect to "private" class II determinants.

    Search related documents:
    Co phrase search for related documents
    • anti ia monoclonal antibody and autoreactivity development: 1
    • anti ia monoclonal antibody and class II determinant: 1
    • anti ia monoclonal antibody and common public epitope class II determinant: 1
    • anti ia monoclonal antibody and CsA therapy: 1
    • autoreactive cell and class II determinant: 1, 2
    • autoreactive cell and common public epitope class II determinant: 1, 2
    • autoreactive cell and CsA therapy: 1
    • autoreactivity development and class II determinant: 1
    • autoreactivity development and common public epitope class II determinant: 1
    • autoreactivity development and CsA therapy: 1
    • class II determinant and common public epitope class II determinant: 1, 2
    • class II determinant and CsA therapy: 1
    • common public epitope class II determinant and CsA therapy: 1